Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3871042 | 1.00 | CYP1A2 (0.37) | CYP1A2CYP2D6CYP2C19GAANOS3 | |
| SCHEMBL3871047 | 1.00 | CYP1A2 (0.37) | CYP1A2CYP2D6CYP2C19GAANOS3 | |
| SCHEMBL11237471 | 0.93 | CYP1A2 (0.36) | CYP1A2CYP2D6CYP2C19GAAKDM4E | |
| SCHEMBL3863861 | 0.92 | TSHR (0.36) | CYP1A2CYP2D6CYP2C19NOS1NOS2 | |
| SCHEMBL3863858 | 0.92 | TSHR (0.36) | CYP1A2CYP2D6CYP2C19NOS1NOS2 | |
| SCHEMBL3863855 | 0.92 | TSHR (0.36) | CYP1A2CYP2D6CYP2C19NOS1NOS2 | |
| SCHEMBL3873512 | 0.86 | ALDH1A1 (0.33) | GAAKDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL3873509 | 0.86 | ALDH1A1 (0.33) | GAAKDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL3873505 | 0.86 | ALDH1A1 (0.33) | GAAKDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL10454264 | 0.78 | KMT2A (0.30) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1845078-B1 | PROCESS FOR PRODUCING LARGE CYCLIC KETONE AND INTERMEDIATE THEREFOR | TAKASAGO PERFUMERY CO LTD (JP) | 2017-06-07 | — | — | EP | disclosed |
| US-7479574-B2 | Method of producing macrocyclic ketone, and intermediate thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-01-20 | — | — | US | disclosed |
| US-20070287870-A1 | Method of Producing Macrocyclic Ketone, and Intermediate Thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-12-13 | — | — | US | disclosed |
| EP-1845078-A1 | PROCESS FOR PRODUCING LARGE CYCLIC KETONE AND INTERMEDIATE THEREFOR | Takasago International Corporation (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287870-A1 | Method of Producing Macrocyclic Ketone, and Intermediate Thereof | MSMO1, CYP17A1, DNMT1 | CYP1A2 33/4885CYP2D6 163/4885CYP2C19 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.